Literature DB >> 21754765

1-Acetyl-6-bromo-1H-imidazo[4,5-b]pyridin-2(3H)-one.

Siham Dahmani, Youssef Kandri Rodi, Santiago V Luis, El Mokhtar Essassi, Lahcen El Ammari.   

Abstract

The two fused five- and six-membered rings in the mol-ecule of the title compound, C(8)H(6)BrN(3)O(2), are approximately coplanar, the largest deviation from the mean plane being 0.011 (3) Å at the NH atom. The acetyl group is slightly twisted with respect to the imidazo[4,5-b]pyridine system, making a dihedral angle of 2.7 (2)°. In the crystal, adjacent mol-ecules are linked by inter-molecular N-H⋯N and C-H⋯O hydrogen bonds, forming infinite chains.

Entities:  

Year:  2011        PMID: 21754765      PMCID: PMC3120304          DOI: 10.1107/S1600536811017004

Source DB:  PubMed          Journal:  Acta Crystallogr Sect E Struct Rep Online        ISSN: 1600-5368


Related literature

For background information on the pharmacological activities of imidazo[4,5-b]pyridines, see: Kale et al. (2009 ▶); Silverman (2004 ▶); Cristalli et al. (1995 ▶); Cundy et al. (1997 ▶); Banie et al. (2007 ▶); Mader (2008 ▶); Janssens et al. (1985 ▶); Bavetsias et al. (2007 ▶); Coates et al. (1993 ▶).

Experimental

Crystal data

C8H6BrN3O2 M = 256.07 Triclinic, a = 4.8302 (15) Å b = 9.645 (3) Å c = 9.809 (3) Å α = 81.542 (7)° β = 85.735 (7)° γ = 89.676 (8)° V = 450.8 (2) Å3 Z = 2 Mo Kα radiation μ = 4.53 mm−1 T = 298 K 0.41 × 0.16 × 0.11 mm

Data collection

Bruker APEXII CCD diffractometer Absorption correction: multi-scan (SADABS; Bruker, 2009 ▶) T min = 0.423, T max = 0.607 2559 measured reflections 1685 independent reflections 1583 reflections with I > 2σ(I) R int = 0.019

Refinement

R[F 2 > 2σ(F 2)] = 0.028 wR(F 2) = 0.074 S = 1.07 1685 reflections 128 parameters H-atom parameters constrained Δρmax = 0.43 e Å−3 Δρmin = −0.48 e Å−3 Data collection: APEX2 (Bruker, 2009 ▶); cell refinement: SAINT (Bruker, 2009 ▶); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 ▶); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 ▶); molecular graphics: ORTEPIII (Burnett & Johnson, 1996 ▶) and ORTEP-3 for Windows (Farrugia, 1997 ▶); software used to prepare material for publication: SHELXL97. Crystal structure: contains datablocks I, global. DOI: 10.1107/S1600536811017004/dn2682sup1.cif Structure factors: contains datablocks I. DOI: 10.1107/S1600536811017004/dn2682Isup2.hkl Supplementary material file. DOI: 10.1107/S1600536811017004/dn2682Isup3.cml Additional supplementary materials: crystallographic information; 3D view; checkCIF report
C8H6BrN3O2Z = 2
Mr = 256.07F(000) = 252
Triclinic, P1Dx = 1.887 Mg m3
Hall symbol: -P 1Melting point: 507 K
a = 4.8302 (15) ÅMo Kα radiation, λ = 0.71073 Å
b = 9.645 (3) ÅCell parameters from 1685 reflections
c = 9.809 (3) Åθ = 2.1–26.0°
α = 81.542 (7)°µ = 4.53 mm1
β = 85.735 (7)°T = 298 K
γ = 89.676 (8)°Fiber, colourless
V = 450.8 (2) Å30.41 × 0.16 × 0.11 mm
Bruker APEXII CCD diffractometer1685 independent reflections
Radiation source: fine-focus sealed tube1583 reflections with I > 2σ(I)
graphiteRint = 0.019
φ and ω scansθmax = 26.0°, θmin = 2.1°
Absorption correction: multi-scan (SADABS; Bruker, 2009)h = −5→5
Tmin = 0.423, Tmax = 0.607k = −11→11
2559 measured reflectionsl = 0→12
Refinement on F2Primary atom site location: structure-invariant direct methods
Least-squares matrix: fullSecondary atom site location: difference Fourier map
R[F2 > 2σ(F2)] = 0.028Hydrogen site location: inferred from neighbouring sites
wR(F2) = 0.074H-atom parameters constrained
S = 1.07w = 1/[σ2(Fo2) + (0.0374P)2 + 0.2048P] where P = (Fo2 + 2Fc2)/3
1685 reflections(Δ/σ)max = 0.001
128 parametersΔρmax = 0.43 e Å3
0 restraintsΔρmin = −0.48 e Å3
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes.
Refinement. Refinement of F2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F2, conventional R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > 2σ(F2) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F2 are statistically about twice as large as those based on F, and R- factors based on ALL data will be even larger.
xyzUiso*/Ueq
C1−0.0666 (6)0.9228 (3)0.7492 (3)0.0412 (6)
H1−0.09120.97890.66540.049*
C20.1373 (5)0.8216 (3)0.7536 (2)0.0371 (5)
C30.1881 (5)0.7340 (3)0.8759 (2)0.0377 (5)
H30.32530.66580.87960.045*
C40.0199 (5)0.7562 (3)0.9904 (2)0.0355 (5)
C5−0.1838 (5)0.8602 (3)0.9766 (3)0.0372 (5)
C6−0.2202 (6)0.7636 (3)1.2009 (3)0.0435 (6)
C70.1715 (7)0.5870 (3)1.1871 (3)0.0466 (6)
C80.1168 (8)0.5301 (3)1.3357 (3)0.0588 (8)
H8A0.23480.45101.35900.088*
H8B−0.07400.50121.35340.088*
H8C0.15410.60131.39090.088*
N1−0.2322 (5)0.9436 (2)0.8618 (2)0.0426 (5)
N2−0.3244 (5)0.8613 (3)1.1034 (2)0.0435 (5)
H2−0.46010.91641.11910.052*
N3−0.0003 (5)0.6957 (2)1.1302 (2)0.0395 (5)
O1−0.2966 (5)0.7398 (2)1.3223 (2)0.0595 (6)
O20.3528 (6)0.5462 (3)1.1138 (2)0.0757 (8)
Br10.35286 (6)0.80290 (3)0.58804 (2)0.04632 (13)
U11U22U33U12U13U23
C10.0412 (14)0.0477 (14)0.0338 (13)0.0047 (11)−0.0012 (10)−0.0033 (10)
C20.0392 (14)0.0439 (13)0.0276 (11)−0.0007 (10)0.0057 (10)−0.0072 (9)
C30.0387 (14)0.0428 (12)0.0310 (12)0.0059 (10)0.0035 (10)−0.0064 (10)
C40.0369 (13)0.0405 (12)0.0283 (11)0.0025 (10)0.0032 (9)−0.0050 (9)
C50.0330 (13)0.0449 (13)0.0341 (12)0.0037 (10)0.0031 (10)−0.0100 (10)
C60.0405 (15)0.0523 (15)0.0366 (14)0.0057 (11)0.0085 (11)−0.0088 (11)
C70.0598 (18)0.0451 (14)0.0325 (13)0.0098 (12)0.0069 (12)−0.0034 (10)
C80.078 (2)0.0572 (17)0.0349 (15)0.0131 (15)0.0123 (14)0.0039 (12)
N10.0397 (13)0.0504 (12)0.0371 (12)0.0090 (10)−0.0002 (9)−0.0059 (9)
N20.0382 (12)0.0550 (13)0.0359 (12)0.0105 (10)0.0076 (9)−0.0074 (9)
N30.0417 (12)0.0461 (11)0.0287 (10)0.0075 (9)0.0083 (8)−0.0045 (8)
O10.0640 (14)0.0745 (14)0.0354 (11)0.0152 (11)0.0188 (9)−0.0049 (9)
O20.0976 (19)0.0822 (16)0.0386 (11)0.0532 (15)0.0185 (11)0.0060 (10)
Br10.0522 (2)0.0565 (2)0.02805 (16)0.00477 (12)0.00836 (11)−0.00472 (11)
C1—N11.354 (3)C6—O11.209 (3)
C1—C21.381 (4)C6—N21.363 (4)
C1—H10.9300C6—N31.433 (3)
C2—C31.398 (4)C7—O21.193 (4)
C2—Br11.894 (2)C7—N31.409 (4)
C3—C41.379 (3)C7—C81.486 (4)
C3—H30.9300C8—H8A0.9600
C4—C51.401 (4)C8—H8B0.9600
C4—N31.406 (3)C8—H8C0.9600
C5—N11.319 (3)N2—H20.8600
C5—N21.374 (3)
N1—C1—C2122.6 (2)N2—C6—N3105.9 (2)
N1—C1—H1118.7O2—C7—N3118.5 (2)
C2—C1—H1118.7O2—C7—C8123.7 (3)
C1—C2—C3122.0 (2)N3—C7—C8117.8 (2)
C1—C2—Br1118.30 (19)C7—C8—H8A109.5
C3—C2—Br1119.66 (19)C7—C8—H8B109.5
C4—C3—C2115.1 (2)H8A—C8—H8B109.5
C4—C3—H3122.5C7—C8—H8C109.5
C2—C3—H3122.5H8A—C8—H8C109.5
C3—C4—C5119.2 (2)H8B—C8—H8C109.5
C3—C4—N3134.3 (2)C5—N1—C1115.0 (2)
C5—C4—N3106.5 (2)C6—N2—C5110.9 (2)
N1—C5—N2125.6 (2)C6—N2—H2124.6
N1—C5—C4126.0 (2)C5—N2—H2124.6
N2—C5—C4108.4 (2)C4—N3—C7124.2 (2)
O1—C6—N2127.0 (3)C4—N3—C6108.4 (2)
O1—C6—N3127.1 (3)C7—N3—C6127.4 (2)
N1—C1—C2—C3−0.5 (5)N1—C5—N2—C6−178.9 (3)
N1—C1—C2—Br1179.6 (2)C4—C5—N2—C60.7 (3)
C1—C2—C3—C40.1 (4)C3—C4—N3—C70.3 (5)
Br1—C2—C3—C4−179.98 (19)C5—C4—N3—C7−179.4 (3)
C2—C3—C4—C50.5 (4)C3—C4—N3—C6−179.8 (3)
C2—C3—C4—N3−179.2 (3)C5—C4—N3—C60.5 (3)
C3—C4—C5—N1−0.8 (4)O2—C7—N3—C42.8 (5)
N3—C4—C5—N1178.9 (3)C8—C7—N3—C4−177.5 (3)
C3—C4—C5—N2179.5 (2)O2—C7—N3—C6−177.1 (3)
N3—C4—C5—N2−0.7 (3)C8—C7—N3—C62.6 (5)
N2—C5—N1—C1−179.9 (3)O1—C6—N3—C4−179.6 (3)
C4—C5—N1—C10.5 (4)N2—C6—N3—C40.0 (3)
C2—C1—N1—C50.2 (4)O1—C6—N3—C70.3 (5)
O1—C6—N2—C5179.1 (3)N2—C6—N3—C7179.8 (3)
N3—C6—N2—C5−0.4 (3)
D—H···AD—HH···AD···AD—H···A
N2—H2···N1i0.862.022.877 (3)175.
C3—H3···O2ii0.932.563.481 (3)172.
Table 1

Hydrogen-bond geometry (Å, °)

D—H⋯AD—HH⋯ADAD—H⋯A
N2—H2⋯N1i0.862.022.877 (3)175
C3—H3⋯O2ii0.932.563.481 (3)172

Symmetry codes: (i) ; (ii) .

  7 in total

1.  2-phenylimidazopyridines, a new series of Golgi compounds with potent antiviral activity.

Authors:  Homayon Banie; Anjana Sinha; Richard J Thomas; Jagadish C Sircar; Mark L Richards
Journal:  J Med Chem       Date:  2007-10-31       Impact factor: 7.446

2.  A short history of SHELX.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr A       Date:  2007-12-21       Impact factor: 2.290

3.  Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38alpha MAP kinase inhibitors with excellent in vivo antiinflammatory properties.

Authors:  Mary Mader; Alfonso de Dios; Chuan Shih; Rosanne Bonjouklian; Tiechao Li; Wesley White; Beatriz López de Uralde; Concepción Sánchez-Martinez; Miriam del Prado; Carlos Jaramillo; Eugenio de Diego; Luisa M Martín Cabrejas; Carmen Dominguez; Carlos Montero; Timothy Shepherd; Robert Dally; John E Toth; Arindam Chatterjee; Sehila Pleite; Jaime Blanco-Urgoiti; Leticia Perez; Mario Barberis; María José Lorite; Enrique Jambrina; C Richard Nevill; Paul A Lee; Richard C Schultz; Jeffrey A Wolos; Li C Li; Robert M Campbell; Bryan D Anderson
Journal:  Bioorg Med Chem Lett       Date:  2007-11-01       Impact factor: 2.823

4.  Cyclic nucleotide phosphodiesterase inhibition by imidazopyridines: analogues of sulmazole and isomazole as inhibitors of the cGMP specific phosphodiesterase.

Authors:  W J Coates; B Connolly; D Dhanak; S T Flynn; A Worby
Journal:  J Med Chem       Date:  1993-05-14       Impact factor: 7.446

5.  New antihistaminic N-heterocyclic 4-piperidinamines. 3. Synthesis and antihistaminic activity of N-(4-piperidinyl)-3H-imidazo[4,5-b]pyridin-2-amines.

Authors:  F Janssens; J Torremans; M Janssen; R A Stokbroekx; M Luyckx; P A Janssen
Journal:  J Med Chem       Date:  1985-12       Impact factor: 7.446

6.  Synthesis and biological evaluation of N6-cycloalkyl derivatives of 1-deazaadenine nucleosides: a new class of anti-human immunodeficiency virus agents.

Authors:  G Cristalli; S Vittori; A Eleuteri; R Volpini; E Camaioni; G Lupidi; N Mahmood; F Bevilacqua; G Palù
Journal:  J Med Chem       Date:  1995-09-29       Impact factor: 7.446

7.  Hit generation and exploration: imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases.

Authors:  Vassilios Bavetsias; Chongbo Sun; Nathalie Bouloc; Jóhannes Reynisson; Paul Workman; Spiros Linardopoulos; Edward McDonald
Journal:  Bioorg Med Chem Lett       Date:  2007-10-22       Impact factor: 2.823

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.